Targeted Tuberculosis Testing and Interpreting Tuberculin Skin Test Results
Targeted tuberculosis (TB) testing is used to focus program activities, provider practices, and financial resources on groups at the highest risk for latent tuberculosis infection (LTBI). Once TB disease has been ruled out, those who would benefit from treatment of LTBI should be offered this option regardless of their age.
Every effort should be made to test only those persons at the highest risk, interpret tuberculin skin test (TST) reactions and TB blood test results accurately, and ensure appropriate treatment and completion of the recommended regimen.
Persons at Risk for Developing TB Disease
Generally, persons at high risk for developing TB disease fall into two categories: those who have an increased likelihood of exposure to persons with TB disease, and those with clinical conditions that increase the risk of progression from LTBI to TB disease.
Persons at risk for exposure to persons with TB disease include:
- Close contacts of a person with infectious TB disease
- Persons who have immigrated from areas of the world with high rates of TB
- Residents and employees of high-risk congregate settings (e.g. correctional facilities, homeless shelters, health care facilities)
Persons more likely to progress from LTBI to TB disease include:
- Recent converters (those with an increase of 10 mm or more in size of TST reaction within a 2-year period)
- HIV–infected persons
- Young children who have a positive TST result
- Those with a history of prior, untreated TB or fibrotic lesions on chest radiograph
- Injection drug users
- Those receiving TNF-α antagonists for treatment of rheumatoid arthritis or Crohn’s disease
Clinical conditions that increase the risk of progression from LTBI to TB disease:
- HIV infection
- Low body weight (> 10% below ideal)
- Diabetes mellitus
- Chronic renal failure or being on hemodialysis
- Jejunoileal bypass
- Solid organ transplant
- Head and neck cancer
Table 1: Criteria for Classifying Positive TST Reactions
|Positive IGRA result or a TST reaction of 5 or more millimeters of induration is considered positive in||Positive IGRA result or a TST reaction of 10 or more millimeters of induration is considered positive in|
Positive IGRA result or a TST Reaction of 15 or more millimeters of induration is considered positive in
- Persons with no known risk factors for TB*
* Although skin testing programs should be conducted only among high-risk groups, certain individuals may require TST for employment or school attendance. An approach independent of risk assessment is not recommended by CDC or the American Thoracic Society.
Questions often arise about the interpretation of TST results in persons with a history of Bacille Calmette-Gurin (BCG) vaccine, HIV infection, and recent contacts to an infectious TB case.
BCG vaccine is currently used in many parts of the world to protect infants and children from severe TB disease, especially TB meningitis. It does not confer lifelong immunity, and its significance in persons receiving the TST causes confusion in the medical and lay community.
- History of BCG vaccine is NOT a contraindication for tuberculin skin testing
- TST reactivity caused by BCG vaccine generally wanes with time
- If more than 5 years have elapsed since administration of BCG vaccine, a positive TST reaction is most likely a result of M. tuberculosis infection
Persons who are HIV infected have a much greater risk for progression to TB disease if they have LTBI.
- Individuals with HIV infection may be unable to mount an immune response to the TST and may have false-negative TST results
- Usefulness of anergy testing in TST-negative persons who are HIV infected has not been demonstrated
Persons with a positive TST result who are contacts of an individual with infectious TB should be treated regardless of age.
- Some TST-negative persons should also be considered for treatment (i.e., young children, immunosuppressed)
- Repeat TST in 8–10 weeks if initial test result is negative. A delayed-type hypersensitivity response to tuberculin is detected 2–8 weeks after infection
- ATS/CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49 (No. RR- 6).
- Targeted Tuberculosis (TB) Testing and Treatment of Latent TB Infection (slide set)
- ATS/CDC. Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection. MMWR 2003; 52 (No. 31).
- CDC. Tuberculosis Associated with Blocking Agents Against Tumor Necrosis Factor – Alpha – California, 2002–2003. MMWR 2004; 53 (No. 30).
- ATS/CDC. Treatment of tuberculosis. MMWR 2003; 52(No. RR-11).
- TB Education and Training Resources website
- World Health Organization (WHO) website
- Treatment of Latent Tuberculosis Infection: Maximizing Adherence (factsheet)
- Treatment Options for Latent Tuberculosis Infection (factsheet)
- Page last reviewed: September 1, 2012
- Page last updated: December 15, 2011
- Content source: